îæ€çŽ¢
îæ€çŽ¢
î
Akoustis Technologies Ord Shs
AKTSîãŠã©ãããªã¹ãã«è¿œå
18.090USD
+0.250+1.40%
çµå€Â 04/15, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
2.80Bæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± Akoustis Technologies Ord Shs äŒæ¥å
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
Akoustis Technologies Ord Shsã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãAKTS
äŒç€ŸåAktis Oncology Inc
äžå Žæ¥Jan 09, 2026
æé«çµå¶è²¬ä»»è
ãCEOãRoden (Matthew)
åŸæ¥å¡æ°117
蚌åžçš®é¡Ordinary Share
決ç®ææ«Jan 09
æ¬ç€Ÿæåšå°17 Drydock Avenue
éœåžBOSTON
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·02210
é»è©±çªå·13026587581
ãŠã§ããµã€ãhttps://www.aktisoncology.com/
äŒæ¥ã³ãŒãAKTS
äžå Žæ¥Jan 09, 2026
æé«çµå¶è²¬ä»»è
ãCEOãRoden (Matthew)
Akoustis Technologies Ord Shsã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.00K
--
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board of Director
Chairman of the Board of Director
2.10K
--
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Kyle D. Kuvalanka
Mr. Kyle D. Kuvalanka
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Akos Czibere, M.D.
Mr. Akos Czibere, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ken Herrmann, M.D.
Mr. Ken Herrmann, M.D.
Independent Director
Independent Director
--
--
Ms. Helen S. Kim
Ms. Helen S. Kim
Independent Director
Independent Director
--
--
Dr. Andrew Levin, M.D., Ph.D.
Dr. Andrew Levin, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Independent Director
Independent Director
--
--
Mr. Lloyd M. Segal
Mr. Lloyd M. Segal
Independent Director
Independent Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.00K
--
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board of Director
Chairman of the Board of Director
2.10K
--
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Kyle D. Kuvalanka
Mr. Kyle D. Kuvalanka
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Akos Czibere, M.D.
Mr. Akos Czibere, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ken Herrmann, M.D.
Mr. Ken Herrmann, M.D.
Independent Director
Independent Director
--
--
åçå èš³
é貚: USDæŽæ°æå»: Sat, Jan 10
é貚: USDæŽæ°æå»: Sat, Jan 10
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
Asia
5.84M
64.74%
Americas
2.43M
26.95%
Europe
750.00K
8.31%
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: 2 hours ago
æŽæ°æå»: 2 hours ago
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
MPM BioImpact LLC
19.21%
Eli Lilly and Company
11.88%
VV Manager LLC
10.92%
EcoR1 Capital, LLC
9.03%
BlackRock Institutional Trust Company, N.A.
1.19%
ä»ã®
47.76%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
MPM BioImpact LLC
19.21%
Eli Lilly and Company
11.88%
VV Manager LLC
10.92%
EcoR1 Capital, LLC
9.03%
BlackRock Institutional Trust Company, N.A.
1.19%
ä»ã®
47.76%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor/Hedge Fund
28.97%
Corporation
11.88%
Venture Capital
10.92%
Investment Advisor
2.21%
Individual Investor
0.40%
ä»ã®
45.62%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Sat, Jan 10
æŽæ°æå»: Sat, Jan 10
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2026Q1
184
21.93M
41.01%
-7.10M
2025Q4
188
74.33K
0.05%
-32.41M
2025Q3
209
74.33K
0.05%
-35.90M
2025Q2
236
74.33K
0.05%
-41.95M
2025Q1
251
315.89K
0.20%
-42.44M
2024Q4
266
839.61K
0.54%
-43.07M
2024Q3
283
21.16M
13.70%
-24.03M
2024Q2
288
25.38M
23.18%
-30.85M
2024Q1
283
43.24M
43.52%
-1.29M
2023Q4
287
31.11M
40.06%
-14.76M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
MPM BioImpact LLC
10.26M
19.21%
+10.26M
--
Jan 12, 2026
Eli Lilly and Company
6.34M
11.88%
+6.34M
--
Jan 12, 2026
VV Manager LLC
5.83M
10.92%
+5.83M
--
Jan 12, 2026
EcoR1 Capital, LLC
4.82M
9.03%
+4.82M
--
Jan 12, 2026
Fidelity Management & Research Company LLC
555.55K
1.04%
+555.55K
--
Jan 31, 2026
Wellington Management Company, LLP
208.41K
0.39%
+208.41K
--
Jan 31, 2026
Driehaus Capital Management, LLC
143.14K
0.27%
+143.14K
--
Jan 31, 2026
Feldman (Paul L. Ph.D.)
118.28K
0.22%
+118.28K
--
Jan 09, 2026
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Jan 10
æŽæ°æå»: Sat, Jan 10
éæå
æ¯ç
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 3000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
æ¯ç0%
Avantis US Small Cap Equity ETF
æ¯ç0%
iShares Micro-Cap ETF
æ¯ç0%
iShares Russell 2000 Growth ETF
æ¯ç0%
iShares Russell 2000 ETF
æ¯ç0%
iShares Russell 3000 ETF
æ¯ç0%
Global X Russell 2000 ETF
æ¯ç0%
ProShares UltraPro Russell2000
æ¯ç0%
Proshares Ultra Russell 2000
æ¯ç0%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
ããŒã¿ãªã
